HTA is multi-disciplinary field of policy analysis that examines the medical, economic, social and ethical implications of the incremental value, diffusion and use of a health technology in health care.
The term Health Technology refers to application of organised knowledge and skills in the form of devices, medicines, vaccines, procedures and systems developed to solve a health problem and improve quality of life.
People suffering from certain types of heart failure, or an abnormal heart rate or rhythm, may have one ofseveral electronic devices implanted (e.g., a defibrillator or […]
Cardiovascular disease is a major public health issue accounting for almost 17 million deaths per year globally. According to estimates, 40-50% of them are sudden cardiac […]
Permanent cardiac pacing using pacemaker implantation is an effective and necessary treatment for patients suffering from atrial fibrillation and bradycardia. In this single technology assessment, we assessed a […]
The aim of this article is to review the role of Health Technology Assessment (HTA) organisations in appraising and recommending innovative cardiovascular technologies. We consider how bias impairs the […]
Retinitis pigmentosa is an eye disease people are born with. People who have it slowly lose their vision. The Argus II retinal implant is the only […]
Cardiac arrhythmia is a group of conditions in which the heart is beating too fast, too slow, or erratically. Symptoms of arrhythmia may include chest pain, […]
Treatment-resistant hypertension is a prevalent and life-threatening condition. At present, renal denervation is the most used non-pharmaceutical therapeutic approach. Optimal medical therapy (OMT) is the current standard.The aim […]
Prostate cancer is the second most common cancer in men in Canada. It forms in the prostate gland of the male reproductive system and often grows […]
The report focuses on the use of AEDs as a standalone intervention, i.e. not incorporated into a coordinated public access defibrillation (PAD) programme, because this is currently the dominant […]
In Norway, breast cancer screening is offered through a publicly funded program to women in the age group 50-69 on a biennial basis. Breast cancer incidence is […]